PLoS ONE (Jan 2023)

Amygdalar activity measured using FDG-PET/CT at head and neck cancer staging independently predicts survival.

  • Malek Z O Hassan,
  • Ahmed Tawakol,
  • Ying Wang,
  • Raza M Alvi,
  • Magid Awadalla,
  • Maeve Jones-O'Connor,
  • Rula B Bakar,
  • Dahlia Banerji,
  • Adam Rokicki,
  • Lili Zhang,
  • Connor P Mulligan,
  • Michael T Osborne,
  • Azmaeen Zarif,
  • Basma Hammad,
  • Annie W Chan,
  • Lori J Wirth,
  • Erica T Warner,
  • Roger K Pitman,
  • Katrina A Armstrong,
  • Daniel Addison,
  • Tomas G Neilan

DOI
https://doi.org/10.1371/journal.pone.0279235
Journal volume & issue
Vol. 18, no. 8
p. e0279235

Abstract

Read online

ImportanceThe mechanisms underlying the association between chronic stress and higher mortality among individuals with cancer remain incompletely understood.ObjectiveTo test the hypotheses that among individuals with active head and neck cancer, that higher stress-associated neural activity (ie. metabolic amygdalar activity [AmygA]) at cancer staging associates with survival.DesignRetrospective cohort study.SettingAcademic Medical Center (Massachusetts General Hospital, Boston).Participants240 patients with head and neck cancer (HNCA) who underwent 18F-FDG-PET/CT imaging as part of initial cancer staging.Measurements18F-FDG uptake in the amygdala was determined by placing circular regions of interest in the right and left amygdalae and measuring the mean tracer accumulation (i.e., standardized uptake value [SUV]) in each region of interest. Amygdalar uptake was corrected for background cerebral activity (mean temporal lobe SUV).ResultsAmong individuals with HNCA (age 59±13 years; 30% female), 67 died over a median follow-up period of 3 years (IQR: 1.7-5.1). AmygA associated with heightened bone marrow activity, leukocytosis, and C-reactive protein (PConclusions and relevanceAmygA, quantified on routine 18F-FDG-PET/CT images obtained at cancer staging, independently and robustly predicts mortality and cancer progression among patients with HNCA. Future studies should test whether strategies that attenuate AmygA (or its downstream biological consequences) may improve cancer survival.